NEW YORK (GenomeWeb) – Investment firm BTIG upgraded shares of molecular diagnostics firm T2 Biosystems, citing the market potential for a bacteria sepsis panel the company has under development.
Analyst Karen Koski upgraded T2 to a Buy rating from Neutral, putting a $16 target price on the company's shares. During late morning trading Friday, T2 stock was trading at $11.19.